Compare Ishares Msci Brazil ETF (EWZ) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Merck & Co., Inc. — how do they compare? Ishares Msci Brazil ETF trades at $35.37, while Merck & Co., Inc. trades at $128.55 (market cap $305.29B). The key difference: Merck & Co., Inc. pays a 2.75% dividend while Ishares Msci Brazil ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Ishares Msci Brazil ETF nearer its low. Which is the better fit depends on your goals.
| EWZ | MRK | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $41.75 | $129.52 |
52-Week Low | $26.52 | $77.60 |
Market Cap | — | $305.29B |
Enterprise Value | — | $348.71B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $35.33, down 1.94% on the day, yet maintains a bullish technical signal with strong moving average support. The ETF has gained approximately 11% year-to-date, driven by Brazil's monetary easing cycle and commodity strength. Recent news highlights Brazil's economic initiatives and the ETF's exposure to Latin America's equity rally, though key financial ratios like P/E and P/B are not provided in the snapshot.
The outlook for EWZ is cautiously optimistic, with potential upside from Brazil's rate cuts and commodity tailwinds, but risks include economic volatility and reliance on key holdings like Petrobras and Vale. Investors should weigh the concentrated exposure and external factors affecting emerging markets.
Merck (MRK) trades at $128.00, up 5.96% on the day. The stock shows a bullish technical signal with strong moving average support, while fundamentals reveal robust profitability with a 73.91% gross margin and consistent earnings beats in recent quarters. The company is actively expanding its oncology pipeline through acquisitions, most notably the $6.7 billion tender offer for Terns Pharmaceuticals announced in April 2026.
The outlook is positive, supported by strong analyst consensus (67.57% Buy rating) and a price target implying ~7% upside. Key opportunities include pipeline expansion via M&A and solid cash flow generation. Primary risks involve integration of large acquisitions, patent cliffs for key drugs, and intense competition in the oncology space, which could pressure future growth margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
